Search details
1.
A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer.
Breast Cancer Res
; 26(1): 3, 2024 01 03.
Article
in English
| MEDLINE | ID: mdl-38173005
2.
European value-based healthcare benchmarking: moving from theory to practice.
Eur J Public Health
; 34(1): 44-51, 2024 Feb 05.
Article
in English
| MEDLINE | ID: mdl-37875008
3.
Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer.
Nat Commun
; 14(1): 3130, 2023 05 30.
Article
in English
| MEDLINE | ID: mdl-37253733
4.
Health care costs of breast, prostate, colorectal and lung cancer care by clinical stage and cost component.
Gac Sanit
; 36(3): 246-252, 2022.
Article
in English
| MEDLINE | ID: mdl-33612313
5.
Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment.
J Clin Invest
; 132(7)2022 04 01.
Article
in English
| MEDLINE | ID: mdl-35192545
6.
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.
Breast
; 66: 77-84, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36206609
7.
The Pseudokinase TRIB3 Negatively Regulates the HER2 Receptor Pathway and Is a Biomarker of Good Prognosis in Luminal Breast Cancer.
Cancers (Basel)
; 13(21)2021 Oct 22.
Article
in English
| MEDLINE | ID: mdl-34771470
8.
Probabilistic cost-utility analysis and expected value of perfect information for the Oncotype multigenic test: a discrete event simulation model.
Gac Sanit
; 34(1): 61-68, 2020.
Article
in English
| MEDLINE | ID: mdl-30442434
9.
Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals.
Clinicoecon Outcomes Res
; 10: 189-199, 2018.
Article
in English
| MEDLINE | ID: mdl-29593426
10.
Health care costs of breast, prostate, colorectal and lung cancer care by clinical stage and cost component / Costes de la atención de los cánceres de mama, próstata, colorrectal y pulmón por estadio clínico y componente de coste
Gac. sanit. (Barc., Ed. impr.)
; 36(3): 246-252, may. - jun. 2022. tab, graf
Article
in English
| IBECS (Spain) | ID: ibc-209245
11.
Spatial intratumoural heterogeneity in the expression of GIT1 is associated with poor prognostic outcome in oestrogen receptor positive breast cancer patients with synchronous lymph node metastases.
F1000Res
; 6: 1606, 2017.
Article
in English
| MEDLINE | ID: mdl-29862012
12.
Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment.
J Clin Invest
; 132(19)2022 10 03.
Article
in English
| MEDLINE | ID: mdl-36169029
13.
Probabilistic cost-utility analysis and expected value of perfect information for the Oncotype multigenic test: a discrete event simulation model / Análisis de coste-utilidad probabilístico y valor esperado de la información perfecta para el test multigénico Oncotype: un modelo de simulación de eventos discretos
Gac. sanit. (Barc., Ed. impr.)
; 34(1): 61-68, ene.-feb. 2020. tab, graf
Article
in English
| IBECS (Spain) | ID: ibc-195416
14.
SEOM clinical guidelines for the treatment of metastatic breast cancer.
Clin Transl Oncol
; 12(11): 719-23, 2010 Nov.
Article
in English
| MEDLINE | ID: mdl-20974562
15.
¿Se puede evitar la linfadenectomía axilar en pacientes con cáncer de mama precoz con ganglio centinela positivo? / Can axillary lymphadenectomy be avoided in patients with sentinel node-positive early breast cancer?
Rev. senol. patol. mamar. (Ed. impr.)
; 26(3): 75-76, jul.-sept. 2013.
Article
in Spanish
| IBECS (Spain) | ID: ibc-115457
Results
1 -
15
de 15
1
Next >
>>